Mercado Global de Espasmo Hemifacial – Tendências da Indústria e Previsão para 2028

Análise e insights de mercado: Mercado global de espasmo hemifacial

Espera-se que o mercado de espasmo hemifacial ganhe crescimento de mercado no período de previsão de 2021 a 2028. A Data Bridge Market Research analisa que o mercado está a crescer a um CAGR de 5,00% no período de previsão de pesquisa acima mencionado. Aumento da população geriátrica e fácil disponibilidade de ferramentas de diagnóstico para caracterização da doença e reconhecimento da gravidade da doença, entre outros.

A fácil disponibilidade de medicamentos anticonvulsivantes e o aumento da incidência de tremor craniofacial, coreia facial, juntamente com o aumento de pacientes não atendidos, também precisam de impulsionar o crescimento do mercado. Além disso, o aumento da parceria e colaboração entre os players do mercado, a presença de reembolso e o aumento da investigação e desenvolvimento para a inovação de novas abordagens de tratamento funcionam como uma oportunidade para o crescimento do mercado. No entanto, a falta de profissionais qualificados para realizar um diagnóstico eficiente, o elevado custo do tratamento, os efeitos secundários associados à toxina botulínica e as regulamentações rigorosas podem dificultar o mercado global dos espasmos hemifaciais .

Hemifacial spasm, a neuromuscular disorder recognized by the frequent involuntary contractions of the muscles present on one side of the face. This disorder affects both men as well as women, however middle aged or elderly women are more likely to affected. The most common symptoms associated with hemifacial spasm include intermittent twitching of eyelid muscle that leads to forced closure of eyes. Gradually the spasm progress towards lower face that result pulling of facial muscles from one side.  Hemifacial spasm can be caused due to tumor or facial nerve injury. Moreover as per the observations of doctors hemifacial spasm occurs due to pressing of blood vessel pressing the facial nerve at the place where its exits the brain stem. The treatment of hemifacial spams includes the use of anticonvulsant drugs, muscle relaxants, physical therapy, combinational therapy, transcutaneous electrical nerve stimulation therapy among others. Among several types of therapies available botulinum toxin therapy is widely accepted therapy indicated for treatment of hemifacial spasm. Moreover in severe cases invasive treatment approaches are also adopted which involves surgical treatment. The surgical treatment used for hemifacial spams includes microvascular decompression among others which relaxes the pressure over the facial nerves.

Hemifacial spasm is one of the rare conditions and its estimated prevalence worldwide reported to be 14.5 cases per 100,000 women and 7.4 among every 100,000 men. The hemifacial spasm are most likely to affect geriatric population of 40 years and above that. As geriatric population increasing at a rapid rate throughout the world, it can lead to rising number of hemifacial spams cases which ultimately demands effective treatment approaches hence expected to provide market with the lucrative growth.

This hemifacial spasm market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Hemifacial Spasm Market Scope and Market Size

Hemifacial spasm market is segmented on the basis of treatment, route of administration, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of treatment, the hemifacial spasm market is segmented into oral medication, botulinum toxin and surgery. Oral medication is further sub- segmented into carbamazepine, gabapentin, benzodiazepines (clonazepam), anticholinergics, baclofen, haloperidol, among others. Botulinum toxin is sub-segmented into type A and type B.
• On the basis of route of administration, the hemifacial spasm market is segmented into oral, parenteral, others.
• On the basis of end-users, the hemifacial spasm market is segmented into clinics, hospitals, homecare, others.
• On the basis of distribution channel, the hemifacial spasm market has also been segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy, others. 

Hemifacial spasm Market Country Level Analysis

Hemifacial spasm market is analysed and market size information is provided by country, type, treatment, end-users and distribution channel as referenced above.

The countries covered in the hemifacial spasm market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

On geographical estimation, North America accounts the largest market share due to rising number of geriatric patients and well-established health care facilities. Europe accounts the second largest market share due to easy availability of anticonvulsant drugs and growing awareness towards neurological disorders. Asia-Pacific is expected to account for the largest market share over coming years for the hemifacial spasm market due to increasing demand of effective therapies and rapidly changing health care infrastructure along with easy availability of drugs.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

O mercado do espasmo hemifacial também fornece análises de mercado detalhadas para análise de pacientes, prognóstico e curas. Prevalência, incidência, mortalidade, taxas de adesão são algumas das variáveis ​​de dados disponíveis no relatório. As análises de impacto direto ou indireto da epidemiologia para o crescimento do mercado são analisadas para criar um modelo estatístico multivariado mais robusto e de coorte para prever o mercado no período de crescimento.

Análise do cenário competitivo e da quota de mercado do espasmo hemifacial

O cenário competitivo do mercado de espasmo hemifacial fornece detalhes por concorrente, os detalhes incluídos são a visão geral da empresa, finanças da empresa, receita gerada, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produto , pipelines de ensaios clínicos, aprovações de produtos, patentes, largura e amplitude de produtos, domínio de aplicação, curva de segurança da tecnologia. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado dos espasmos hemifaciais.

Os principais players abrangidos no mercado do espasmo hemifacial são a Pfizer Inc., Mylan NV, F. Hoffmann-La Roche AG, Novartis AG, Allergan plc., Piramal Critical Care, Inc., Apotex Inc., Shire Plc e Validus Pharmaceuticals LLC. , DAEWOONG PHARMACEUTICAL CO., LTD., Evolus, Inc., USWM, LLC., Revance, Cyclo Therapeutics, Inc., Medytox, Hughs, Merz Pharma, Ipsen Pharma, HUGEL, Inc., Eisai Co., Ltd., AlphaVax entre outros players nacionais e globais. Os analistas DBMR compreendem os pontos fortes competitivos e fornecem análises competitivas para cada concorrente em separado.

SKU-60168